Pharmaceutical Investing Alnylam Completes Enrollment in ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias
Fortune Minerals Reports Successful NICO Project Bismuth Test Work Results for the Planned Alberta Refinery